{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:36:51Z","timestamp":1786534611632,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":69,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Stichting Aidsfonds","award":["P-42701 and P- 54201"],"award-info":[{"award-number":["P-42701 and P- 54201"]}]},{"name":"Gilead Sciences","award":["21341"],"award-info":[{"award-number":["21341"]}]},{"name":"GGD Amsterdam","award":["2021-5 and 2022-2"],"award-info":[{"award-number":["2021-5 and 2022-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04949-y","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:44:04Z","timestamp":1780569844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of reduced-frequency monitoring among users of HIV pre-exposure prophylaxis on sexually transmitted infections and associated care: secondary outcomes of a randomized controlled trial"],"prefix":"10.1186","volume":"24","author":[{"given":"Eline S.","family":"Wijstma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije L.","family":"Groot Bruinderink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita W.","family":"Jongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders C.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Blitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"van Bokhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joey","family":"Woudstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koenraad","family":"Vermey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Boers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore M.","family":"G\u00f6tz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frenk","family":"van Harreveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elske","family":"Hoornenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi","family":"Davidovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten F.","family":"Schim van der Loeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"5","key":"4949_CR1","doi-asserted-by":"publisher","first-page":"e1004328","DOI":"10.1371\/journal.pmed.1004328","volume":"21","author":"MAM van den Elshout","year":"2024","unstructured":"van den Elshout MAM, Wijstma ES, Boyd A, Jongen VW, Coyer L, Anderson PL, et al. Sexual behaviour and incidence of sexually transmitted infections among men who have sex with men (MSM) using daily and event-driven pre-exposure prophylaxis (PrEP): four-year follow-up of the Amsterdam PrEP (AMPrEP) demonstration project cohort. PLoS Med. 2024;21(5):e1004328.","journal-title":"PLoS Med"},{"issue":"10","key":"4949_CR2","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3018(24)00211-X","volume":"11","author":"MS Torres Silva","year":"2024","unstructured":"Torres Silva MS, Torres TS, Coutinho C, Ismerio Moreira R, da Costa Leite I, Cunha M, et al. Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study. Lancet HIV. 2024;11(10):e670\u2013e9.","journal-title":"Lancet HIV"},{"issue":"12","key":"4949_CR3","doi-asserted-by":"publisher","first-page":"e790","DOI":"10.1016\/S2352-3018(23)00256-4","volume":"10","author":"AK Sullivan","year":"2023","unstructured":"Sullivan AK, Saunders J, Desai M, Cartier A, Mitchell HD, Jaffer S, et al. HIV pre-exposure prophylaxis and its implementation in the PrEP impact trial in England: a pragmatic health technology assessment. Lancet HIV. 2023;10(12):e790\u2013e806.","journal-title":"Lancet HIV"},{"key":"4949_CR4","unstructured":"Centers for Disease Control and Prevention. Clinical Guidance for PrEP 2024 [updated 20 August 2024. Available from: https:\/\/www.cdc.gov\/hivnexus\/hcp\/prep\/"},{"key":"#cr-split#-4949_CR5.1","unstructured":"Nederlandse multidisciplinaire richtlijn Preexpositieprofylaxe (PrEP) ter preventie van hiv - update 2022. 11-07-2022 ed. Amsterdam: Nederlandse Vereniging van Hiv Behandelaren"},{"key":"#cr-split#-4949_CR5.2","unstructured":"2022. Accessed 30 May 2026 from: https:\/\/www.soaaids.nl\/files\/2022-07\/20220711-PrEP-richtlijn-Nederland-versie-3-update-2022.pdf"},{"issue":"8","key":"4949_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/sextrans-2020-054741","volume":"97","author":"F van Wifferen","year":"2021","unstructured":"van Wifferen F, Hoornenborg E, Schim van der Loeff MF, Heijne J, van Hoek AJ. Cost-effectiveness of two screening strategies for Chlamydia trachomatis and Neisseria gonorrhoeae as part of the PrEP programme in the Netherlands: a modelling study. Sex Transm Infect. 2021;97(8):607\u201312.","journal-title":"Sex Transm Infect"},{"key":"4949_CR7","unstructured":"Groot Bruinderink M, Deuring, A, de Vries, L, G\u00f6tz, HM, Blitz, L, Boers, S, et al. Needs assessment towards online and less frequent PrEP monitoring: focus group perspectives from young and migrant men who have sex with men and transgender persons in the Netherlands [Poster Abstract: WEPED415]. International AIDS Conference; 22-26 July 2024; Munich, Germany:2024. Accessed on 2 June 2026 from: https:\/\/www.iasociety.org\/sites\/default\/files\/AIDS2024\/abstract-book\/AIDS-2024_Abstracts.pdf"},{"issue":"2","key":"4949_CR8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10461-023-04232-8","volume":"28","author":"A Rotsaert","year":"2024","unstructured":"Rotsaert A, Vanhamel J, Vanbaelen T, Vuylsteke B, van der Loeff MS, Hensen B, et al. HIV Pre-exposure prophylaxis (PrEP) care in belgium: a mixed-methods study on PrEP users\u2019 experiences and service delivery preferences. AIDS Behav. 2024;28(2):393\u2013407.","journal-title":"AIDS Behav"},{"issue":"1","key":"4949_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/sextrans-2025-056506","volume":"102","author":"VW Jongen","year":"2025","unstructured":"Jongen VW, Schim van der Loeff M, van Wees DA, van den Elshout M, Hoebe CJPA, G\u00f6tz HM, et al. Regression-based risk scores using sociodemographic and sexual behaviour data do not predict asymptomatic sexually transmitted infections among HIV PrEP users. Sex Transm Infect. 2025;102(1):17\u201323.","journal-title":"Sex Transm Infect"},{"issue":"13","key":"4949_CR10","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1097\/QAD.0000000000003676","volume":"37","author":"VW Jongen","year":"2023","unstructured":"Jongen VW, Van Der Loeff MFS, Van Den Elshout M, Wijstma E, Coyer L, Davidovich U, et al. Bacterial sexually transmitted infections are concentrated in subpopulations of men who have sex with men using HIV pre-exposure prophylaxis. AIDS. 2023;37(13):2059\u201368.","journal-title":"AIDS"},{"key":"4949_CR11","volume-title":"Sexually Transmitted Diseases","author":"KK Holmes","year":"2007","unstructured":"Holmes KK, Sparling PF, Stamm WE, Piot P, Wasserheit JN, Corey L, et al. Sexually Transmitted Diseases. 4th ed. McGraw-Hill Professional; 2007.","edition":"4th ed."},{"key":"4949_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100743","volume":"34","author":"C Kenyon","year":"2023","unstructured":"Kenyon C, Herrmann B, Hughes G, de Vries HJC. Management of asymptomatic sexually transmitted infections in Europe: towards a differentiated, evidence-based approach. Lancet Reg Health Eur. 2023;34:100743.","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"4949_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nri1551","volume":"5","author":"RC Brunham","year":"2005","unstructured":"Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol. 2005;5(2):149\u201361.","journal-title":"Nat Rev Immunol"},{"key":"4949_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1248613","volume":"14","author":"T Belcher","year":"2023","unstructured":"Belcher T, Rollier CS, Dold C, Ross JDC, MacLennan CA. Immune responses to Neisseria gonorrhoeae and implications for vaccine development. Front Immunol. 2023;14:1248613.","journal-title":"Front Immunol"},{"issue":"5","key":"4949_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/OLQ.0b013e3181ca3c0a","volume":"37","author":"RT Gray","year":"2010","unstructured":"Gray RT, Hoare A, Prestage GP, Donovan B, Kaldor JM, Wilson DP. Frequent testing of highly sexually active gay men is required to control syphilis. Sex Transm Dis. 2010;37(5):298\u2013305.","journal-title":"Sex Transm Dis"},{"issue":"5","key":"4949_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1093\/cid\/cix439","volume":"65","author":"SM Jenness","year":"2017","unstructured":"Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis. 2017;65(5):712\u20138.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4949_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1097\/QAD.0000000000002522","volume":"34","author":"EC Tang","year":"2020","unstructured":"Tang EC, Vittinghoff E, Philip SS, Doblecki-Lewis S, Bacon O, Chege W, et al. Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis. AIDS. 2020;34(8):1181\u20136.","journal-title":"AIDS"},{"issue":"3","key":"4949_CR18","first-page":"149","volume":"99","author":"VW Jongen","year":"2023","unstructured":"Jongen VW, Zimmermann HML, Goedhart M, Bogaards JA, Davidovich U, Coyer L, et al. Can we screen less frequently for STI among PrEP users? Assessing the effect of biannual STI screening on timing of diagnosis and transmission risk in the AMPrEP Study. Sex Transm Infect. 2023;99(3):149\u201355.","journal-title":"Sex Transm Infect"},{"issue":"9","key":"4949_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/OLQ.0000000000000824","volume":"45","author":"A Tsoumanis","year":"2018","unstructured":"Tsoumanis A, Hens N, Kenyon CR. Is screening for chlamydia and gonorrhea in men who have sex with men associated with reduction of the prevalence of these infections? A systematic review of observational studies. Sex Transm Dis. 2018;45(9):615\u201322.","journal-title":"Sex Transm Dis"},{"issue":"3","key":"4949_CR20","doi-asserted-by":"publisher","first-page":"e0248582","DOI":"10.1371\/journal.pone.0248582","volume":"16","author":"U Marcus","year":"2021","unstructured":"Marcus U, Mirandola M, Schink SB, Gios L, Schmidt AJ. Changes in the prevalence of self-reported sexually transmitted bacterial infections from 2010 and 2017 in two large European samples of men having sex with men-is it time to re-evaluate STI-screening as a control strategy? PLoS One. 2021;16(3):e0248582.","journal-title":"PLoS One"},{"key":"4949_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.12688\/f1000research.17955.1","volume":"8","author":"C Kenyon","year":"2019","unstructured":"Kenyon C. Screening is not associated with reduced incidence of gonorrhoea or chlamydia in men who have sex with men (MSM); an ecological study of 23 European countries. F1000Res. 2019;8:160.","journal-title":"F1000Res"},{"issue":"12","key":"4949_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101214","volume":"6","author":"T Vanbaelen","year":"2025","unstructured":"Vanbaelen T, De Baetselier I, Tsoumanis A, Hensen B, Kenyon C. Effect of decreasing the frequency of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on the incidence of these infections and antimicrobial use among men who have sex with men using HIV PrEP in Belgium: a retrospective cohort study. Lancet Microbe. 2025;6(12):101214.","journal-title":"Lancet Microbe"},{"key":"4949_CR23","doi-asserted-by":"publisher","first-page":"e51023","DOI":"10.2196\/51023","volume":"12","author":"ML Groot Bruinderink","year":"2023","unstructured":"Groot Bruinderink ML, Boyd A, Coyer L, Boers S, Blitz L, Brand JM, et al. Online-mediated HIV pre-exposure prophylaxis care and reduced monitoring frequency for men who have sex with men: protocol for a randomized controlled noninferiority trial (EZI-PrEP Study). JMIR Res Protoc. 2023;12:e51023.","journal-title":"JMIR Res Protoc"},{"key":"4949_CR24","unstructured":"Groot Bruinderink ML, Boyd A, Werner L, Jongen VW, Blitz L, van Bokhoven C, et al. Online and less frequent monitoring of oral HIV PrEP use are noninferior to standard of care. Conference on Retroviruses and Opportunistic Infections; 10 March 2025; San Francisco, CA, USA: 2025. Accessed on 2 June 2026 from: https:\/\/www.croiconference.org\/abstract\/898-2025\/"},{"key":"4949_CR25","unstructured":"Hoornenborg ERB, Wielinga GJ, Hogewoning A, Burger D, Hermanussen R, Heijnen A, et al.,. HIV Pre-expositie profylaxe richtlijn Nederland [HIV pre-exposure prophylaxis (PrEP) guideline Netherlands] Accessed on 30 May 2026 from https:\/\/nvhb.nl\/wp-content\/uploads\/2019\/04\/PrEP-richtlijn-Nederland-versie-2-dd-15-april-2019.pdf"},{"key":"4949_CR26","unstructured":"Nederlandse Vereniging van HIV-behandelaren, Soa Aids Nederland. Multidisciplinaire richtlijn seksueel overdraagbare aandoeningen (soa) 2018: Update 2019 Amsterdam: Soa Aids Nederland; 2019. Accessed 30 May 2026 from: https:\/\/www.soaaids.nl\/files\/2019-07\/multidisciplinair-richtlijn-soa-2018-update-2019.pdf"},{"key":"4949_CR27","unstructured":"Nederlandse Vereniging voor Dermatologie en Venereologie. Multidisciplinaire richtlijn SOA (herziening 2022\u20132024) [PDF]. 2024. Accessed 30 May 2026 from: https:\/\/www.soaaids.nl\/files\/2024-07\/mdr-multidisciplinaire-richtlijn-soa-herziening-2022-2024.pdf"},{"key":"4949_CR28","unstructured":"Kayaert LS, Visser D, Willemstein M, Alexiou IJM, van Bergen ZW, Kusters I et al. Sexually transmitted infections in the Netherlands in 2023. 2024. Accessed 30 May 2026 from: https:\/\/www.rivm.nl\/publicaties\/sexually-transmitted-infections-in-netherlands-in-2023"},{"key":"4949_CR29","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2025. Oslo, Norway, 2024. Accessed 1 December 2025 from: https:\/\/atcddd.fhi.no\/filearchive\/publications\/1_2025_guidelines_for_atc_classification_and_ddd_assignment.pdf"},{"key":"4949_CR30","doi-asserted-by":"publisher","unstructured":"Groot Bruinderink ML, Schim van der Loeff MF, Dusseldorp F, van der Velde K, Blitz L, Brand J-M, et al. Representativeness of participants in a randomized controlled trial on modalities of monitoring oral HIV pre-exposure prophylaxis use. AIDS Res Ther. 2026 Apr 13. Epub ahead of print. PMID: 41975506. https:\/\/doi.org\/10.1186\/s12981-026-00886-1","DOI":"10.1186\/s12981-026-00886-1"},{"issue":"4","key":"4949_CR31","first-page":"219","volume":"99","author":"B Teker","year":"2023","unstructured":"Teker B, de Vries H, Heijman T, van Dam A, Schim van der Loeff M, Jongen VW. Spontaneous clearance of asymptomatic anogenital and pharyngeal Neisseria gonorrhoeae: a secondary analysis from the NABOGO trial. Sex Transm Infect. 2023;99(4):219\u201325.","journal-title":"Sex Transm Infect"},{"issue":"7","key":"4949_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/sextrans-2018-053825","volume":"95","author":"G van Liere","year":"2019","unstructured":"van Liere G, Hoebe C, Dirks JA, Wolffs PF, Dukers-Muijrers N. Spontaneous clearance of urogenital, anorectal and oropharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women, MSM and heterosexual men visiting the STI clinic: a prospective cohort study. Sex Transm Infect. 2019;95(7):505\u201310.","journal-title":"Sex Transm Infect"},{"issue":"8","key":"4949_CR33","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/sextrans-2020-054500","volume":"96","author":"S Mensforth","year":"2020","unstructured":"Mensforth S, Ayinde OC, Ross J. Spontaneous clearance of genital and extragenital Neisseria gonorrhoeae: data from GToG. Sex Transm Infect. 2020;96(8):556\u201361.","journal-title":"Sex Transm Infect"},{"issue":"9","key":"4949_CR34","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1097\/OLQ.0000000000000807","volume":"45","author":"IPY Hananta","year":"2018","unstructured":"Hananta IPY, de Vries HJC, van Dam AP, van Rooijen MS, Soebono H, Schim van der Loeff MF. Spontaneous clearance of pharyngeal gonococcal infections: a retrospective study in patients of the sexually transmitted infections clinic; Amsterdam, the Netherlands; 2012 to 2015. Sex Transm Dis. 2018;45(9):594\u20139.","journal-title":"Sex Transm Dis"},{"issue":"3","key":"4949_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/sextrans-2014-051633","volume":"91","author":"MS van Rooijen","year":"2015","unstructured":"van Rooijen MS, van der Loeff MF, Morre SA, van Dam AP, Speksnijder AG, de Vries HJ. Spontaneous pharyngeal Chlamydia trachomatis RNA clearance. A cross-sectional study followed by a cohort study of untreated STI clinic patients in Amsterdam, The Netherlands. Sex Transm Infect. 2015;91(3):157\u201364.","journal-title":"Sex Transm Infect"},{"issue":"12","key":"4949_CR36","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1177\/09564624211025940","volume":"32","author":"T Vanbaelen","year":"2021","unstructured":"Vanbaelen T, Van Dijck C, De Baetselier I, Florence E, Reyniers T, Vuylsteke B, et al. Screening for STIs is one of the main drivers of macrolide consumption in PrEP users. Int J STD AIDS. 2021;32(12):1183\u20134.","journal-title":"Int J STD AIDS"},{"issue":"4","key":"4949_CR37","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1016\/S2352-3018(23)00299-0","volume":"11","author":"Vanbaelen T","year":"2024","unstructured":"Vanbaelen T, Tsoumanis A, Florence E, Van Dijck C, Huis In \u2018t Veld D, Sauvage AS, et al. Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial. Lancet HIV. 2024;11(4):e233\u2013e44.","journal-title":"Lancet HIV"},{"key":"4949_CR38","volume-title":"Antimicrobial stewardship","author":"J Shrestha","year":"2024","unstructured":"Shrestha J, Zahra F, Cannady J Jr. Antimicrobial stewardship [Updated 2023 Jun 20] In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572068\/"},{"key":"4949_CR39","unstructured":"Tudor ME, Al Aboud, AM, Leslie, SW,, Gossman, W Syphilis. [Updated 2024 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. From: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK534780\/."},{"issue":"11","key":"4949_CR40","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1097\/QAD.0000000000004224","volume":"39","author":"ES Wijstma","year":"2025","unstructured":"Wijstma ES, Jongen VW, Boyd A, De Vries HJC, Van Der Loeff MFS, Prins M, et al. Subpopulations with frequent healthcare barriers have increased risk of sexually transmitted infections and dropping out from HIV preexposure prophylaxis care. AIDS. 2025;39(11):1610\u201320.","journal-title":"AIDS"},{"key":"4949_CR42","unstructured":"Werner L, Groot Bruinderink, M, van Harreveld, F, Blitz, L, Brand, J, van Bokhoven, C, et al. Usability and users\u2019 preferences for online HIV PrEP care and reduced PrEP monitoring frequency: results from the EZI-PrEP study [Poster Presentation]. Netherlands Conference on HIV Pathogenesis, Epidemiology, Prevention and Treatment (NCHIV). Amsterdam, the Netherlands; 2024."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04949-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04949-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04949-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:03:45Z","timestamp":1786532625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04949-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4949"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04949-y","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The EZI-PrEP Trial was approved by the medical ethics committee of the Amsterdam University Medical Center, file number 2020_154 - NL74494.018.20. The trial has been registered with ClinicalTrials.gov, trial number NCT05093036 (\n                      \n                      ). Written informed consent for study participation was obtained from all participants as part of the eligibility screening procedure.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication was obtained from all participants as part of the eligibility screening procedure.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UD received unrestricted research grants from Gilead Sciences, and participated in Advisory boards of ViiV HealthCare & Gilead Sciences, all fees and grants paid to his institute. MFSvdL participated in Advisory Boards of Merck Sharp & Dohme, for which fees were paid to his institute. MFSvdL received a research grant from GlaxoSmithKline, paid to his institute. EH received unrestricted research grants from Gilead Sciences, paid to her institute. MP received unrestricted research grants and speaker\/advisory fees from Gilead Sciences and Merck Sharp & Dohme, all paid to her institute. AB received speaker\u2019s fees from Gilead Sciences. All other authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"429"}}